0112 GMT - IHH Healthcare's earnings outlook may remain attractive amid rising demand and revenue intensity, particularly in the Indian and Malaysian markets, as key growth drivers, Maybank IB analysts Yin Shao Yang and Nur Natasha Ariza say in a note. Despite the stock's over 20% year-to-date share price gains, valuations indicate potential for a re-rating as IHH pursues both organic and strategic inorganic expansion, they add. The analysts project a 13% compound annual growth rate in three-year forward revenue and Ebitda for IHH. Maybank resumes coverage on IHH with a buy rating and raises its target price to MYR7.97 from MYR7.13. Shares are unchanged at MYR7.23. (yingxian.wong@wsj.com)
(END) Dow Jones Newswires
December 29, 2024 20:12 ET (01:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。